Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department
NCT07726069
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
NOT_YET_RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Cannabinoid Hyperemesis Syndrome
Interventions
DRUG:
Haloperidol
Sponsor
University of Illinois at Chicago